MedKoo Cat#: 412774 | Name: Cgs 26303

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cgs 26303 is a potent non-peptidic inhibitor of neutral endopeptidase capable of protecting atrial natriuretic peptide from enzymatic degradation.

Chemical Structure

Cgs 26303
Cgs 26303
CAS#154116-31-1

Theoretical Analysis

MedKoo Cat#: 412774

Name: Cgs 26303

CAS#: 154116-31-1

Chemical Formula: C16H18N5O3P

Exact Mass: 359.1147

Molecular Weight: 359.33

Elemental Analysis: C, 53.48; H, 5.05; N, 19.49; O, 13.36; P, 8.62

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Cgs 26303; Cgs26303; Cgs-26303
IUPAC/Chemical Name
Phosphonic acid, (((2-(1,1'-biphenyl)-4-yl-1-(1H-tetrazol-5-yl)ethyl)amino)methyl)-, (S)-
InChi Key
UUMKQZVEZSXWBY-HNNXBMFYSA-N
InChi Code
InChI=1S/C16H18N5O3P/c22-25(23,24)11-17-15(16-18-20-21-19-16)10-12-6-8-14(9-7-12)13-4-2-1-3-5-13/h1-9,15,17H,10-11H2,(H2,22,23,24)(H,18,19,20,21)/t15-/m0/s1
SMILES Code
OP(CN[C@H](C1=NN=NN1)CC2=CC=C(C3=CC=CC=C3)C=C2)(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 359.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Wang HC, Cheng KI, Chou CW, Kwan AL, Chang LL. Intrathecal CGS-26303 Pretreatment Attenuates Spinal Nerve Ligation-Induced Neuropathic Pain in the Spinal Cord. World Neurosurg. 2016 Jul;91:532-541.e1. doi: 10.1016/j.wneu.2016.02.093. Epub 2016 Mar 4. PMID: 26947729. 2: Raoch V, Martinez-Miguel P, Arribas-Gomez I, Rodriguez-Puyol M, Rodriguez- Puyol D, Lopez-Ongil S. The peptidase inhibitor CGS-26303 increases endothelin converting enzyme-1 expression in endothelial cells through accumulation of big endothelin-1. Br J Pharmacol. 2007 Oct;152(3):313-22. doi: 10.1038/sj.bjp.0707398. Epub 2007 Jul 23. PMID: 17643133; PMCID: PMC2042959. 3: Chang CZ, Yen CP, Winadi D, Wu SC, Howng SL, Lin TK, Jeng AY, Kassell NF, Kwan AL. Neuroprotective effect of CGS 26303, an endothelin-converting enzyme inhibitor, on transient middle cerebral artery occlusion in rats. J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S487-9. doi: 10.1097/01.fjc.0000166307.86678.d1. PMID: 15838355. 4: Wang CJ, Lee PY, Wu BN, Wu SC, Loh JK, Tsai HP, Chung CL, Kassell NF, Kwan AL. Alteration of basilar artery rho-kinase and soluble guanylyl cyclase protein expression in a rat model of cerebral vasospasm following subarachnoid hemorrhage. Biomed Res Int. 2014;2014:531508. doi: 10.1155/2014/531508. Epub 2014 Jun 1. PMID: 24982890; PMCID: PMC4058103. 5: Lin CL, Kwan AL, Dumont AS, Su YF, Kassell NF, Wang CJ, Wu SC, Kuo CL, Huang CS, Jeng AY, Liu CS. Attenuation of experimental subarachnoid hemorrhage-induced increases in circulating intercellular adhesion molecule-1 and cerebral vasospasm by the endothelin-converting enzyme inhibitor CGS 26303. J Neurosurg. 2007 Mar;106(3):442-8. doi: 10.3171/jns.2007.106.3.442. PMID: 17367067. 6: Emoto N, Raharjo SB, Isaka D, Masuda S, Adiarto S, Jeng AY, Yokoyama M. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats. Hypertension. 2005 Jun;45(6):1145-52. doi: 10.1161/01.HYP.0000168944.29525.da. Epub 2005 May 16. PMID: 15897363. 7: Yen CP, Chen SC, Lin TK, Wu SC, Chang CY, Lue SI, Jeng AY, Kassell NF, Kwan AL. CGS 26303 upregulates mRNA expression of heme oxygenase-1 in brain tissue of rats subjected to experimental subarachnoid hemorrhage. J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S474-8. doi: 10.1097/01.fjc.0000166310.71431.52. PMID: 15838352. 8: Henry PJ, Carr MJ, Goldie RG, Jeng AY. The role of endothelin in mediating virus-induced changes in endothelinB receptor density in mouse airways. Eur Respir J. 1999 Jul;14(1):92-7. doi: 10.1034/j.1399-3003.1999.14a16.x. PMID: 10489834. 9: Mulder P, Barbier S, Monteil C, Jeng AY, Henry JP, Renet S, Thuillez C. Sustained improvement of cardiac function and prevention of cardiac remodeling after long-term dual ECE-NEP inhibition in rats with congestive heart failure. J Cardiovasc Pharmacol. 2004 Apr;43(4):489-94. doi: 10.1097/00005344-200404000-00003. PMID: 15085059. 10: Jeng AY, De Lombaert S, Beil ME, Bruseo CW, Savage P, Chou M, Trapani AJ. Design and synthesis of a potent and selective endothelin-converting enzyme inhibitor, CGS 35066. J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S36-9. doi: 10.1097/00005344-200036051-00014. PMID: 11078330.